Edwards announces six-month data confirming teer as safe and effective for dmr in first head-to-head trial

Boston , sept. 17, 2022 /prnewswire/ -- edwards lifesciences corporation (nyse: ew) announced results from clasp iid, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (teer) therapies.
EW Ratings Summary
EW Quant Ranking